Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal for Fabry Disease
-Scheduled for Today, October 29, 2010 at 8:30 a.m. Eastern Time-
CRANBURY, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will host a live conference call and webcast today, October 29, 2010 at 8:30 a.m. Eastern Time to discuss the Company's exclusive worldwide agreement with GlaxoSmithKline PLC to develop and commercialize Amigal (migalastat HCl) for the treatment of Fabry disease.
Interested participants and investors may access the conference call today at 8:30 a.m. Eastern Time by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. Eastern Time. Access numbers for this replay are 800-642-1687 (U.S./Canada) and 706-645-9291 (international); participant code 20951935.
A live audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.
Amicus' press releases are available at www.amicustherapeutics.com.
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and CNS diseases. Amicus' lead program is in Phase 3 for the treatment of Fabry disease.
SOURCE Amicus Therapeutics
Thomas, Director, Investor Relations of Amicus Therapeutics,
Web Site: http://www.amicustherapeutics.com
Posted: October 2010
Recommended for you